Christina Rossi
Patrimonio netto: - $ in data 31/08/2026
Patrimonio netto: - $ in data 31/08/2026
Christina Rossi is currently Director at CG Oncology, Inc. since 2025.
Former roles include Independent Director at Xilio Therapeutics, Inc. from 2021 to 2026; Chief Operating Officer at Blueprint Medicines Corp.
from 2022 to 2025; Head-Multiple Sclerosis Business Unit at Genzyme Corp.
from 2012 to 2018; Head-Multiple Sclerosis Business North America at Genzyme Therapeutics Ltd. from 2016 to 2018; and Head-Commercial Strategy at Eidetica Biopharma GmbH from 2005 to 2010.
Education includes an undergraduate degree from Duke University in 1997 and an MBA from Harvard Business School in 2003.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 04/06/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CG ONCOLOGY, INC. | Direttore/Membro del Consiglio | 24/11/2025 |
| Società | Posizione | Fine |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 15/04/2026 |
| BLUEPRINT MEDICINES CORPORATION | Direttore operativo | 01/01/2025 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/10/2018 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01/10/2018 |
Eidetica Biopharma GmbH
Eidetica Biopharma GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical drugs | Corporate Officer/Principal | 01/01/2010 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 8 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Eidetica Biopharma GmbH
Eidetica Biopharma GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical drugs | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale